Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06611111 · ClinicalTrials.gov registry record · Early Phase 1
Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
A Early Phase 1 study of Post-Treatment Lyme Disease, sponsored by State University of New York - Upstate Medical University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06611111 is a Early Phase 1 study of Post-Treatment Lyme Disease that is actively recruiting participants, run by State University of New York - Upstate Medical University. The registered enrollment target is 44 participants, roughly in line with the 48-participant average among 4 other Post-Treatment Lyme Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06611111, a Early Phase 1 study of Post-Treatment Lyme Disease, is actively recruiting participants, sponsored by State University of New York - Upstate Medical University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if an FDA approved drug, Ceftriaxone, given intermittently, can treat people between 18 and 75 years old with a history of Lyme disease, who are still experiencing persistent or returning symptoms after they have completed treatment. The main questions it aims to answer are: * Will giving Ceftriaxone approximately every 5 days for 6 weeks be safe and well tolerated when compared to a group that receives placebo (a look-alike substance that contains no drug)? * Will giving Ceftriaxone improve symptoms? Participants will be asked to do the following: * Come to the clinic approximately every 5-6 days to receive an IV infusion of either the Ceftriaxone or placebo. * Answer questions about their level of tiredness, body pain, general health and physical ability, sleep, anxiety, depression and any suicidal thoughts. * Give blood so we can make sure your body is handling the drug okay or to help us learn more about how the drug is affecting the persistent Lyme disease symptoms.
Conditions Studied
Interventions
- DRUG Ceftriaxone (Rocephin®)
- DRUG Dextrose 5% (D5W)
Study Locations (1)
New York
- SUNY Upstate Medical University, Upstate Global Health Institute - East Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06611111
The ClinicalTrials.gov registry entry for NCT06611111 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 48-participant average among 4 other Post-Treatment Lyme Disease trials with a reported enrollment target. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post-Treatment Lyme Disease appearing as the primary indexed condition, and to 2 interventions - of which Ceftriaxone (Rocephin®) is the first listed.
NCT06611111 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06611111 about?
NCT06611111 is a clinical study titled "Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease". The goal of this clinical trial is to learn if an FDA approved drug, Ceftriaxone, given intermittently, can treat people between 18 and 75 years old with a history of Lyme disease, who are still experiencing persistent or returning symptoms after they have completed treatment. The main questions it ...
What is the current status of trial NCT06611111?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 44 participants. The study started on 2025-02-03. Estimated completion is 2026-12.
What conditions does trial NCT06611111 study?
This clinical trial studies the following conditions: Post-Treatment Lyme Disease.
What interventions are being tested in trial NCT06611111?
The interventions under investigation include: Ceftriaxone (Rocephin®) (DRUG), Dextrose 5% (D5W) (DRUG).
Who is sponsoring clinical trial NCT06611111?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06611111 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-Treatment Lyme Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
RECRUITING
-
Transcranial Direct Current Stimulation for Post Treatment Lyme Disease
RECRUITING · NA
-
taVNS for Persistent Symptoms From Lyme Disease
RECRUITING · NA
-
Navigating Pregnancy and Parenthood With Lyme Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.